Abstract
Report description
The Partnering Agreements in Diagnostics report provides comprehensive
understanding and unprecedented access to the diagnostic partnering agreements
entered into by the worlds leading healthcare companies. The report provides a
detailed understanding and analysis of how and why companies enter diagnostic
partnering deals. The majority of deals are development stage whereby the
licensee obtains a right or an option right to license the licensors
diagnostic technology or product candidates. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner' s negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 500 links to online copies of actual diagnostic
contract documents as submitted to the Securities Exchange Commission by
companies and their partners. Contract documents provide the answers to
numerous questions about a prospective partner' s flexibility on a wide range
of important issues, many of which will have a significant impact on each
party' s ability to derive value from the deal. The initial chapters of this
report provide an orientation of diagnostic dealmaking and business
activities. Chapter 1 provides an introduction to the report, whilst chapter 2
provides an overview of diagnostic dealmaking since 2000. The chapter includes
numerous case studies to enable understanding of diagnostic dealmaking.
Chapter 3 provides an overview of the trends in diagnostic dealmaking since
2000.
Chapter 4 provides a review of the leading diagnostic deals since 2000. Deals
are listed by headline value, signed by bigpharma, most active bigpharma, and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of diagnostic
contract documents available in the public domain. Where available, each deal
title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of diagnostic
partnering deals signed and announced since 2003, where a contract document is
available in the public domain. The chapter is organized by company A-Z, stage
of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink
to an online version of the actual contract document, providing easy access to
each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in diagnostic partnering and dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
diagnostic technologies and products.
Key benefits
Partnering Agreements in Diagnostics provides the reader with the following key benefits:
- In-depth understanding of diagnostic deal trends since 2000
- Analysis of the structure of diagnostic agreements with numerous real life
case studies
- Comprehensive access to over 500 actual diagnostic contracts entered into
by the world' s biopharma companies*
- Detailed access to actual diagnostic contracts enter into by the leading
fifty bigpharma companies*
- Insight into the terms included in a diagnostic agreement, together with
real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Report scope
Partnering Agreements in Diagnostics is intended to provide the reader with an
in-depth understanding of the diagnostic trends and structure of deals entered
into by leading companies worldwide.
Partnering Agreements in Diagnostics includes:
- Trends in diagnostic dealmaking in the biopharma industry since 2000
- Analysis of diagnostic deal structure
- Case studies of real-life diagnostic deals
- Access to over 500 diagnostic contract documents
- The leading diagnostic deals by value since 2000
- Most active diagnostic dealmakers since 2000
- The leading diagnostic partnering resources
In Partnering Agreements in Diagnostics, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
The Partnering Agreements in Diagnostics report provides comprehensive access to available contract documents for over 500 diagnostic deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise diagnostic rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
| 
View Cart
